Cranfield's first health conference to focus on translational and regenerative medicine

23 March 2009

Professor Lord Robert Winston is to head a world-class line-up of science professionals and academic speakers at Cranfield Health’s first conference for biomedical scientists and health professionals in June this year.

The Invention for Intervention conference on 25-26 June 2009 will discuss the emerging fields of translational and regenerative medicine and how the parallel fields of the bench scientist and the clinician can cross over to align within the pharmaceutical and biotechnology industries.

Professor Winston, Professor of Science and Society and Emeritus Professor of Fertility, Imperial College, London, will aim to challenge the translational medicine community with his expert opinion.

Other esteemed speakers include Dr John McCafferty, Head of Cell Interaction Group, Department of Biochemistry, University of Cambridge and a founder of Cambridge Antibody Technology, and Professor Enrique Amaya, The Healing Foundation Chair of Tissue Regeneration, University of Manchester.

The one-and-a-half day event is suitable for biomedical scientists, pharmaceutical researchers, academics or anyone with an interest in this field. The conference will highlight how discoveries from the bench can be guided into the clinic, and will span diverse topics from immunological intervention to stem cell and other reparative therapies.

Speakers include:

  •  Professor Enrique Amaya (The Healing Foundation Chair of Tissue Regeneration, University of Manchester)
  •  Mr Alan Getgood (Clinical Research Associate University of Cambridge, Orthopaedic Research Unit)
  •  Professor Nagy Habib (Professor of Hepto-biliary Surgery, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics Department of Surgery, Imperial College, London)
  •  Dr. John McCafferty (Head of Cell Interaction Group, Department of Biochemistry, University of Cambridge and a founder of Cambridge Antibody Technology)
  •  Professor Paul Moss (Head of Cancer Sciences and Cancer Research UK Institute of Studies, University of Birmingham)
  •  Professor Nadia Rosenthal (Chair in Cardiovascular Science and Scientific Director, National Heart and Lung Institute, Imperial College, London)
  •  Dr. Elaine Sullivan (VP Head of Technology Development, AstraZeneca PLC)
  •  Professor Herman Waldmann (Professor of Pathology and Head of Department, Sir William Dunn School of Pathology, University of Oxford).

For more information see: www.invention4intervention.com

Bookmark this page

To top